Moreover, studies such as the European Randomized Study of Screening for PCa (ERSPC) have provided level 1 evidence demonstrating that prostate-specific antigen (PSA) screening reduces PCa-specific mortality by 20% after 16 years of follow-up and metastatic disease by 30% after 12 years [12]. This evidence concerns the gene KLK3 and metastatic neoplasm.